Back to top

oncology-screening: Archive

Zacks Equity Research

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.

LGNDPositive Net Change AGENPositive Net Change ACADPositive Net Change RPTXPositive Net Change